Editorial
|
|
|
|
|
Orlistat without a prescription in the EU
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Heparin is a better-known option
|
|
|
|
|
|
|
|
|
|
|
|
Often uncomfortable and don't expect miracles
|
|
|
|
|
|
|
|
|
|
|
|
Nothing new for first-line therapy
|
|
|
|
|
|
|
|
|
|
Do not modify ongoing therapy
|
|
|
|
|
|
|
|
|
|
Barely more effective than an excipient
|
|
|
|
|
|
|
|
|
|
|
|
Market withdrawal in the EU
|
|
|
|
|
|
|
|
|
|
Insufficient improvement in statural growth
|
|
|
|
|
|
|
|
|
|
|
|
Just another cytotoxic drug
|
|
|
|
|
|
|
|
|
|
EU Marketing application withdrawn
|
|
|
|
|
|
|
|
|
|
Do not use this combination
|
|
|
|
|
|
|
|
|
|
|
|
Lithium remains the standard drug
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
An effective alternative to oral hormonal contraception
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|